Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.73 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.73 |
| ▸ | KDM1A | O60341 | 3/20 | 0.67 |
| ▸ | NPY2R | P49146 | 8/20 | 0.65 |
| ▸ | NPY4R | P50391 | 8/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.65 |
| ▸ | NPY1R | P25929 | 6/20 | 0.65 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | KDM5A | P29375 | 1/20 | 0.61 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.61 |
| ▸ | TFPI | P10646 | 2/20 | 0.60 |
| ▸ | REN | P00797 | 3/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30495769 | 0.89 | MAPK8 (0.69) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL30262210 | 0.89 | KDM1A (0.74) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL30432199 | 0.89 | NPY2R (0.67) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL31182939 | 0.88 | MAPK8 (0.73) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL30436596 | 0.88 | MAPK8 (0.65) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL30658402 | 0.88 | NPY2R (0.68) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL30432934 | 0.88 | MAPK8 (0.72) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL29903341 | 0.88 | NPY2R (0.66) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL30804679 | 0.87 | MAPK8 (0.62) | MAPK8MAPK9MAPK10KDM1ANPY2R | |
| SCHEMBL31182927 | 0.87 | NPY2R (0.71) | KDM1ANPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2026042880-A1 | MODIFIED NYLON HYDROLASE AND USE THEREOF | 国立大学法人 鹿児島大学 | 2026-02-26 | — | — | WO | claimed |
| EP-3984538-B1 | MIGALASTAT FOR USE IN TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | AMICUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | claimed |
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2025016350-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2025-01-23 | — | — | WO | claimed |
| WO-2024245443-A1 | COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-12-05 | — | — | WO | claimed |
| US-11833164-B2 | Methods of treating Fabry disease in patients having a mutation in the GLA gene | AMICUS THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | claimed |
| US-11834490-B2 | CD112 variant immunomodulatory proteins and uses thereof | ALPINE IMMUNE SCIENCES, INC. (US) | 2023-12-05 | — | — | US | claimed |
| EP-4147715-A1 | BIOFUSION PROTEINS AS ANTI-MALARIA VACCINES | VAC4all Pte. Ltd. (SG) | 2023-03-15 | — | — | EP | claimed |
| CN-216817201-U | Control device of multi-door unmanned sales counter | 浙江星星冷链集成股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-114423428-A | Methods of treating fabry disease in patients with mutations in the GLA gene | 阿米库斯治疗学公司 | 2022-04-29 | — | — | CN | claimed |
| EP-3984538-A2 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | Amicus Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12624087-B2 | CD155 variant immunomodulatory proteins and uses thereof | ALPINE IMMUNE SCIENCES, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4732901-A2 | METHODS OF TREATING FABRY DISEASE | Amicus Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260076951-A1 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING RENAL IMPAIRMENT | AMICUS THERAPEUTICS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| CN-114423427-A | Method of treating fabry disease in patients with renal impairment | 阿米库斯治疗学公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3984538-A2 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | Amicus Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220068956-A1 | MEMORY DEVICE INCLUDING MULTIPLE DECKS OF MEMORY CELLS AND PILLARS EXTENDING THROUGH THE DECKS | LODESTAR LICENSING GROUP, LLC | 2022-03-03 | — | — | US | disclosed |
| WO-2022047331-A1 | MULTIPLE DECKS OF MEMORY CELLS AND PILLARS | MICRON TECHNOLOGY, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624087-B2 | CD155 variant immunomodulatory proteins and uses thereof | CD2BP2, CD2, LY96 | MAPK8 2843/4885MAPK9 3244/4885MAPK10 3744/4885 |
| US-11833164-B2 | Methods of treating Fabry disease in patients having a mutation in the GLA gene | GAA, GLA, GBA1 | MAPK8 3399/4885MAPK9 3595/4885MAPK10 3466/4885 |
| US-20260076951-A1 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING RENAL IMPAIRMENT | MME, ERP44, HSPA5 | MAPK8 1177/4885MAPK9 316/4885MAPK10 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.